EVO - Evotec Corp Price-to-Revenue Ratio

Evotec SE maintains high profitability through unique technological platforms, while on GURU.Markets, this linear price-to-sales multiple, with a current parameter of 0.70, confirms the link between profitability and strict adherence to bioethical ESG standards. The active development of R&D outsourcing tools and long-term contracts provide the company with sustainable growth potential for the future.
Analytical breakdowns for Evotec Corp (EVO)

The P/S multiple determines the market value of one dollar of annual revenue, allowing for an assessment of the investor's premium paid for the company's sales volume. Analyzing changes in the P/S multiple helps align the market capitalization of Evotec SE (EVO) with its long-term drug development contracts, where a stable order book makes this indicator a key measure of the scientific platform's monetization efficiency.